Paper Details

  1. Home
  2. Paper Details

The switching process from buprenorphine sublingual tablets to the monthly buprenorphine subcutaneous depot injection in opioid dependent patients.

Author: EngeSören, FahrnerMarius, GuilleryStephanie Paula Elisabeth, HellwegRainer, KronenbergGolo, KunteHagen, ReinersSven

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Switching from sublingual buprenorphine to buprenorphine depot injection (BUP-XR) may be associated with some negative side effects in the first few weeks, but these symptoms appear to diminish over time. This study found that patients experienced worse physical well-being and lower treatment satisfaction four weeks after the switch, but these measures improved at 16 weeks. It is crucial to educate patients about the potential challenges of switching to BUP-XR and provide close supervision during the transition to minimize discomfort and treatment discontinuation.
Paper Details　
Original Abstract of the Article :
The 2018 European Union (EU) approved weekly and monthly subcutaneous buprenorphine depot injection (BUP-XR), for opioid substitution medication proved to offer some specific treatment benefits. The present study examines the process of switching from buprenorphine sublingual tablets (BUP-SL) to BUP...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/adb.13275

データ提供：米国国立医学図書館（NLM）

Switching Gears: Navigating the Transition to Monthly Buprenorphine Injections

Opioid dependence is a complex and challenging condition, and finding effective and sustainable treatment options is essential. This research explores the process of switching from buprenorphine sublingual tablets to a monthly buprenorphine subcutaneous depot injection, a significant shift in medication delivery. This study delves into the patient experience, seeking to understand the challenges and potential benefits of this transition. The findings suggest that while the switch may initially be challenging, with patients experiencing discomfort and potential side effects, long-term outcomes appear more positive. This is a valuable insight for healthcare providers, allowing them to better guide patients through this transition.

The Long and Winding Road: Insights into Medication Switching

The research demonstrates that patients may experience temporary side effects and discomfort during the first few weeks of transitioning to the monthly injection. However, the study emphasizes that these symptoms tend to subside over time, offering a brighter outlook for long-term treatment. This is a critical piece of information for patients and providers alike, allowing them to anticipate and prepare for potential challenges and ultimately achieve more positive outcomes.

Finding Balance: A Guide to Successful Transitions

The research highlights the importance of close supervision and comprehensive patient education during the switch to monthly buprenorphine injections. This can help to minimize negative experiences and encourage successful treatment adherence. A smooth transition, just like a camel caravan navigating a challenging desert with the right guide, can lead to a more comfortable and successful journey.

Dr.Camel's Conclusion

Switching from buprenorphine sublingual tablets to a monthly subcutaneous depot injection can be a challenging process for patients. This research emphasizes the importance of close supervision and comprehensive patient education to support patients through the transition. The study also indicates that while initial discomfort and side effects may be experienced, long-term outcomes appear more positive, offering hope for sustained treatment success.

Date :
  1. Date Completed 2023-05-17
  2. Date Revised 2023-06-06
Further Info :

Pubmed ID

37186443

DOI: Digital Object Identifier

10.1111/adb.13275

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.